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The present issue of Neuro-Oncology Practice has a focus on rare brain tumors, radiotherapy, 
radionecrosis, and supportive and palliative care.  
Using National Cancer Database data, Prabhu and colleagues (pXXX) assessed an association of 
post-operative (“adjuvant”) radiotherapy with outcome in adult patients with intracranial ependymoma. 
No association of administering radiotherapy with survival was detected, although other factors like 
older age and male sex showed such an association. While these data are interesting and somewhat 
surprising, it remains doubtful that uncontrolled data like this will change what has become a common 
practice at many sites. Siddiqui and colleagues (pXXX) provide contemporary data on the risk of 
radiation necrosis after radiosurgery for brain metastasis. The risk per lesion at 4 years was estimated 
at 6.8%, and 60% of patients had an intervention for radiation necrosis. Re-irradiated lesions had a 
radiation necrosis risk at 4 years of 33.3%. Bevacizumab has emerged as probably the most potent 
medical treatment for radiation necrosis and this has now has also been confirmed in children with 
symptomatic radiation necrosis (Baroni et al., pXXX). Long-term survival with adequate health-related 
quality of life has become the major goal of clinical interventions in brain tumor patients. Data on long-
term consequences of brain tumor treatment are still scarce, but cerebrovascular complications are 
increasingly noted. A cross-sectional study from Finland, studying pediatric brain tumor patients after a 
median of 20 years after radiotherapy, confirmed a high rate of 63% of cerebrovascular disease that 
was diagnosed at a median age of 27 years (Remes pXXX). Cerebrovascular disease, small vessel 
disease or large vessel disease were noted in 52%, 38% and 16% of the patients. Six patients had 
experienced a stroke, 2 patients had experienced cerebral hemorrhage. The risk was increased by the 
classical risk factors of cerebrovascular disease like elevated blood pressure and elevated cholesterol 
levels. The authors stress the need for preventive strategies in this patient population, but delaying or 
modifying the dose of radiotherapy should also be considered in treatment-sensitive brain tumors. 
Lu and colleagues (pXXX) review the efficacy and safety of bevacizumab in progressive low-grade 
gliomas in children and identified 7 studies reporting clinical histories of 110 patients who were treated 
with bevacizumab, mostly as part of combination regimens. While the rate of clinical and radiological 
responses was encouraging, there were no controlled data and no conclusions regarding the intrinsic 
activity of bevacizumab alone and an impact on survival could be derived. 
An understudied aspect of cancer chemotherapy for malignant brain tumors of childhood concerns 
proactive enteral tube placements and feeding. Weight loss is a common problem in this patient 
population during treatment. The retrospective analysis by Bendelsmith and colleagues (pXXX) 
illustrates that proactive enteral tube feeding helps to maintain weight or to facilitate weight gain, at 
least over the first year of treatment and was acceptable for the children and their families. 
There have recently been increased efforts in promoting participation of brain tumor patients in clinical 
trials and other research projects. In this regard, Mulhauser and colleagues (pXXX) explored the ability 
to provide informed consent to research in patients with brain metastases, with extra-CNS metastases 
or in healthy controls and, expectedly, found that patients with brain metastases showed lower 
performance in the domain of understanding. The authors conclude with many of our colleagues that 
the current research consent process is simply too complicated, may be even for healthy individuals. 
The advances in molecular neuropathology have resulted in a rather sophisticated subclassification of 
primary brain tumors, including the generation of many new entities for which very little knowledge is 
available in the clinical domain. Papillary tumor of the pineal region is such a rare entity for which little 
guidance for management can be provided. A single center experience from Tübingen, Germany 
(pXXX) suggests that at least half of patients will develop local recurrence after surgery, suggesting 
that further treatment might be worth considering after incomplete resection. Whether this treatment 
should include only radiotherapy or other approaches needs to be studied prospectively. 
The overall limited success of targeted therapy for primary brain tumor patients makes BRAF inhibition 
an attractive option for the few patients with tumors that exhibit mutations of BRAF. However, as 
reported by Schreck and colleagues (pXXX), combined BRAF and MEK inhibition has the potential for 
significant toxicity, notably also since this treatment is usually thought to be required for a long time. 
Information on these caveats of targeted therapy are important for the neuro-oncology community. 
There has recently been major interest in a potential role of cannabis and its derivatives in brain tumor 
patients, including claims of intrinsic antitumor properties. Rodriguez-Almaraz and colleagues (pXXX) 
set out to review the evidence and identified 5 of 45 initial publications for further study. They conclude 
that there was limited “moderate-quality evidence” supporting the use of cannabis as an adjunct to 
standard of care, but it appears that prospective controlled trials are essential before any 
recommendation for the use of such agents can be made. 
Although guidelines uniformly recommend that patients with suspected primary brain tumors should 
undergo a neurosurgical procedure to secure a diagnosis, this is not uniformly adhered to in clinical 
practice. Sometimes such interventions are not thought to be feasible, at least at certain sites or in 
certain regions. There are thus little data on outcome in such patients treated based on imaging alone. 
A report from Toronto, Canada on 61 such patients showed poor outcome for these patients in the 
supratentorial compartment, although survival was 18 months in the brainstem group, raising the 
suspicion that not all these patients may have had malignant gliomas (pXXX). Whenever feasible, 
such patients should be referred to a center where an appropriate surgical intervention, at least by 
biopsy, can be offered.  
Data from the Wake Forest Baptist Comprehensive Cancer Center registry were used by Bower and 
colleagues (pXXX) to study whether community economic factors where associated with outcome in 
patients with primary malignant gliomas. Patients from low income communities indeed experienced 
shorter median overall survival, indicating that the hypothesis of an impact of community economic 
factors may be true. Further studies are required to better understand the potential underlying reasons 
and to explore whether this observation can be extrapolated to other regions within and outside the 
US. 
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